Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital therapy

Mtech Access certified as a NICE META tool facilitating organisation

Mtech Access are now a certified NICE META Tool facilitating organisation, with three experts having passed the NICE assessment

Mtech Access

- PMLiVE

New £5m project launched to bring Alzheimer’s blood tests to the NHS

Blood tests for the condition could become available on the NHS within five years

- PMLiVE

UK antibiotic subscription model found by OHE as key to supporting investment

The OHE report offers valuable insights into investor views of the subscription model

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

- PMLiVE

FDA approves Servier’s Tibsovo as first targeted therapy for rare blood cancer

Approximately 16,000 people in the US are diagnosed with myelodysplastic syndromes every year

- PMLiVE

Bristol Myers Squibb’s Sotyktu recommended by NICE for plaque psoriasis

An estimated 1.8 million people in the UK are affected by some form of the condition

- PMLiVE

Healthware Group report on depression care in Italy highlights need for digital therapeutics

Mental health disorders are the fifth leading cause of disability adjusted life years in Italy

- PMLiVE

AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

The agency said there is not enough evidence of the drug’s effectiveness against current variants

- PMLiVE

Ipsen reports positive phase 3 data for Onivyde in pancreatic cancer

The investigational treatment regimen met its primary endpoint of overall survival

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu recommended by NICE for advanced breast cancer

The treatment has been recommended for use within a managed access arrangement

- PMLiVE

Boehringer Ingelheim’s idiopathic pulmonary fibrosis treatment recommended by NICE

Patients will be eligible for the antifibrotic treatment earlier in the course of their disease

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers

The PD-1 inhibitor demonstrated a statistically significant benefit in overall survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links